Diagnostics

The NASDAQ-listed biotech received a "Study May Proceed" letter for its Phase 2b NDA-enabling study of SkinJect in patients with Gorlin Syndrome.

OraSure's updated rapid antigen test detects all four disease-causing Ebola viruses and was developed with BARDA funding amid a live DRC outbreak.

Alpha Tau's ADMIRE study has dosed its first patient, targeting a population for whom standard checkpoint immunotherapy carries significant organ-rejection risk.

A peer-reviewed study found IGeneX's FDA-cleared IB tests detected early Lyme disease in 58.3% of cases versus 30.0% with standard

RWS has combined COA licensing, translation, linguistic validation and rater training under one programme team to cut delays in global clinical trials.

The DP World-owned brain health facility will offer optional neurological assessments to professional boxers competing in sanctioned UAE events.

Aligos has fully enrolled 245 participants in B-SUPREME, its Phase 2 trial of pevifoscorvir sodium in chronic hepatitis B, with topline data expected in

The Elecsys IGRA TB test processes samples in 19 minutes, cutting standard IGRA turnaround in half and integrating with Roche's existing cobas immunoassay platforms.

Tarsus is acquiring iRenix and its IRX-101 ocular antiseptic, backed by Phase 2b/3 data showing significant pain and corneal toxicity reductions.

Endogenex has fully enrolled its sham-controlled ReCET study of a duodenal pulsed electric field device for type 2 diabetes across 40 sites.

DiamiR Biosciences and AlzLabs will combine protein and microRNA blood biomarkers to improve early detection of Alzheimer's disease.

The Polish diagnostics company secured US patent protection for its non-invasive Panuri test as a European clinical trial enrols its first participants.

A three-layer sensor developed at Vilnius University can detect, identify and locate radiation sources in real time, from lab doses to megagray nuclear emergency

A pooled analysis of 8,478 patients shows Myriad's Prolaris Biopsy Test adds prognostic value beyond standard clinical risk tools in localised prostate cancer.

Belgian particle accelerator firm IBA will supply two Proteus ONE compact systems to IPO-Porto, establishing the country's first proton therapy facility by 2029.

Telix Pharmaceuticals secured FDA agreement on protocol and statistics for Part 2 of its lutetium-177 rosopatamab Phase 3 trial in metastatic prostate cancer.

Seer has defended a key European proteomics patent and launched a US trade investigation targeting Nanomics' competing Proteonano products.

The peer-reviewed Oxford study of 409 men over six years underpins the GPS-ProtecT randomised controlled trial of mdxhealth's 17-gene prostate assay.

Six months after a strategic equity deal, the partners say live deployments cut healthcare processing times by 93% and lifted admissions throughput up to tenfold.

Stockholm3 detected 90% of aggressive prostate cancers versus 52% for standard PSA testing in a large population-based screening trial published in Annals of Internal